silymarin and cisplatin induced nephrotoxicity

Phase 2

Conditions: Condition 1: oesophagus cancer. Condition 2: Stomach Cancer.
Malignant neoplasm of oesophagus
Malignant neoplasm of stomach

Registration Number: IRCT201207013043N6

Lead Sponsor: tehran university of medical science,

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 58

Inclusion Criteria

inclusion criteria (age>18 years; diagnosed and measurale upper gasterointestinal adenocarcinoma; no swallow problem; would like to participate in the study; GFR>45ml/min/1.73m2) Exclusion criteria( end stage renal disease, requiring dialysis, post transplantation; receiving contrast media during last 72 hours; chronic use of corticosteroids; chronic use of ACEI; untreated hypo-and hyperthyroidism; ejection fraction<60%; active urinary tract infection; iver disease (5fold increase of liver enzyme in asymptomatic or 3 fold increase in syptomatic; ; use of other nephrotoxic agents such as aminoglycoside, amphotricin; karnofsky performance status <70)

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rine neutrophil gelatinase-associated lipocalin (NGAL). Timepoint: before chemotherapy and at 6,24 hours after first and third cycle of chemotherapy, day 21 before second cycle. Method of measurement: ELISA kit.;Serum concentration of VEGF and tissue activity of caspase 3. Timepoint: after recruitment and the end of study after three chemotherapy cycle. Method of measurement: ELISA kit.

Secondary Outcome Measures